# Menopause Hormone Replacement Therapy and Lifestyle Factors affect Metabolism and Immune System in the Serum Proteome of Aging Individuals

4

5 Clemens Dierks<sup>1,2</sup>, Roza Sürme Mizrak<sup>1</sup>, Orr Shomroni<sup>1</sup>, Vadim Farztdinov<sup>1,3</sup>, Kathrin Textoris6 Taube<sup>1,3</sup>, Daniela Ludwig<sup>1,3</sup>, Johannes Rainer<sup>4</sup>, Michael Mülleder<sup>3</sup>, Ilja Demuth<sup>5,6</sup>, Markus
7 Ralser<sup>1,7,8\*</sup>

- 8
- 9 <sup>1</sup> Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt
   10 Universität zu Berlin, Institute of Biochemistry, Charitéplatz 1, 10117 Berlin, Germany
- 11 <sup>2</sup> Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt
- 12 Universität zu Berlin, Department of Infectious Diseases, Respiratory Medicine and Critical Care,
- 13 Augustenburger Platz 1, 13353 Berlin, Germany
- <sup>3</sup> Core Facility High Throughput Mass Spectrometry, Charité Universitätsmedizin Berlin, 10117 Berlin,
   Germany
- 16 <sup>4</sup> Institute for Biomedicine, Eurac Research, 39100 Bolzano, Italy
- 17 <sup>5</sup> Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-
- 18 Universität zu Berlin, Department of Endocrinology and Metabolic Diseases (including Division of Lipid
- 19 Metabolism), Biology of Aging working group, Augustenburger Platz 1, 13353 Berlin, Germany
- 20 <sup>6</sup> Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-
- 21 Universität zu Berlin, and Berlin Institute of Health, Regenerative Immunology and Aging, BIH Center
- 22 for Regenerative Therapies, 13353 Berlin, Germany
- 23 <sup>7</sup> Max Planck Institute for Molecular Genetics, 14195 Berlin, Germany
- <sup>8</sup> The Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford,
   Oxford OX3 7BN, UK
- 26
- 27 \* Correspondence: <u>markus.ralser@charite.de</u>

#### 28 Abstract

29 Aging is a fundamental risk factor for a wide array of diseases. The Berlin Aging Study II 30 (BASE-II) is a cohort study designed to investigate the physical, mental, and social determinants of successful aging. We utilized high-throughput mass spectrometry to measure 31 32 the proteomes of 1890 BASE-II participants, divided into two age groups: 27-37 years and 60-33 85 years. We employed multiple linear regression analyses to explore the effects of 34 demographic factors such as age, sex, and BMI, along with hormonal treatments and lifestyle factors, on the serum proteome. We identify new associations and confirm previously 35 36 described proteins linked to age, sex, BMI and hormonal contraceptive use (HCU), Notably, 37 we observed that the abundance of nutrient transport proteins, particularly apolipoproteins, is linked to metabolic diseases in aged individuals, including metabolic syndrome and type 2 38 39 diabetes. Additionally, we identified specific alterations explained by lifestyle factors, such as smoking and alcohol consumption. We further report a significant proteome signature in 40 41 female study participants corresponding to menopause hormone replacement therapy (MHT). 42 We successfully classified these participants based on MHT status with an AUROC of 0.82 43 using two proteins, Complement Component 9 and Plasminogen, slightly outperforming 44 estradiol (AUROC: 0.80), the active ingredient in most MHT preparations. Overall, our study 45 underscores the impact of lifestyle and hormonal therapies on the serum proteome during 46 aging, primarily affecting components of the immune system and metabolism.

#### 47 Introduction

48

49 Aging is a primary risk factor for numerous chronic diseases and is associated with health 50 deterioration and functional decline of the body, making it particularly important to investigate 51 molecular changes that are related to age<sup>1</sup>. While the underlying mechanisms are complex, 52 the serum proteome offers huge potential for deciphering the interrelations of health and 53 disease <sup>2,3</sup>. The serum proteome responds to changes underlying aging, such as increasing 54 levels of inflammatory proteins and decreasing tissue repair and cell regeneration activity <sup>4</sup>. 55 Circulating serum protein level levels can help to differentiate between healthy aging and pathological conditions <sup>1,5-7</sup>. Moreover, an increased understanding of the relationship 56 57 between chronological and biological aging can contribute to delay or prevent diseases where chronological age is a major risk factor <sup>6</sup> as well as improving patient stratification <sup>1</sup>. Identifying 58 markers of healthy aging is crucial to define appropriate lifestyle interventions and thereby 59 60 enhancing lifespan<sup>8</sup>.

61

62 Broadly speaking, the serum contains two sets of proteins. Proteins that function in the blood, such as nutrient transport proteins, signaling molecules, proteins of the immune system and 63 64 the coagulation machinery, and proteins, who circulate in the blood due to tissue leakage, cell 65 necrosis, or to their presence in secreted extracellular vesicles. Several, but not all, of the 66 biomarkers that are currently in use, are part of the former, and are often found within the 67 highly abundant fraction of the plasma proteome, that is easily accessible and simplifies the development of routine applicable biomarker assays 9-12. In recent years, the application of 68 69 multiplexed proteome technologies has enhanced our ability to probe the complex molecular 70 landscape of the proteome in plasma or serum. Recent advancements in mass spectrometry-71 based proteomic platforms have addressed previous challenges related to throughput and 72 cost, enabling large-scale recording of plasma proteomes <sup>13</sup>.


73

74 In this study, we recorded the serum proteomes of 1890 participants from the Berlin Aging 75 Study II (BASE-II)<sup>14</sup> The study aims to uncover factors contributing to healthy aging, involving 76 in total 2200, with about two thirds belonging to the older group aged 60 to 85 years and about 77 one third representing the younger group of participants aged between 27 to 37 years from 78 the metropolitan area of Berlin, Germany. We obtained a quantitative dataset focussing on the 79 neat serum proteome and the high abundant fraction of the serum proteome, and quantifies 80 acute phase proteins, lipid transport proteins, proteins involved in the innate or adaptive 81 immune system and coagulation factors. We report their dependency on age, common 82 disease, selected lifestyle factors, and discover strong signals that are attributable to hormonal 83 replacement therapy.

#### 84 Results

#### 85 Study Profile and Proteomic Assessment of the Berlin Aging Study II

86



87

Figure 1: (A) Study Design. Schematic representation of the 2200 BASE-II participants, 88 89 divided into an older and a younger control group. Serum samples of 1890 participants were 90 analyzed using a high-throughput proteomics platform combining semi-automated sample 91 preparation and latest trapped ion mobility spectrometry. (B) Distribution of coefficient of 92 variation (CV) per protein for study data (gray), pooled study samples (blue) and standardized control serum samples (red) (Violin plots). The line plot depicts proteins ranked by their CV, 93 while barplots show the CV distribution across all proteins. (C) Correlations of sex hormone 94 binding globulin (SHBG), apolipoprotein A1 (APOA1) and B (APOB) concentrations on the y-95 96 axis versus the values obtained with related or corresponding routine diagnostic tests (left to 97 right). Diagnostic test values were transformed to log2 for visualization purposes.

98

99

100 We conducted MS-based proteomic measurements on a total of 2091 serum samples, 101 including 105 serum control and 96 pooled study samples, to generate a proteomic baseline 102 from the BASE-II. The samples analyzed are derived from two age groups: older adults (N = 103 1433) aged 60 to 85 years and younger adults (N = 426) aged 27 to 37 years. Study 104 demographics are given in Table 1.

105 The samples were prepared for measurement in a semi-automatic workflow that allows for 106 high-throughput and consistent sample quality including tryptic digestion and sample cleanup with solid-phase extraction <sup>15</sup>. Samples were divided into 8 batches, each consisting of three 107 108 96-well plates, and were subjected to mass spectrometric measurement using a timsTOF Pro1 109 mass analyzer (Bruker Daltonics) operating in diaPASEF mode, using analytical flow rate chromatography using <sup>16,17</sup>. Raw MS data was processed by DIA-NN <sup>18,19</sup>, using the 110 111 DiOGenes spectral library <sup>20</sup>. In the subsequent preprocessing the data was normalized, 112 filtered for outlier samples and low-presence peptides, imputed and corrected for plate effects 113 (N = 24). Among the data set, 31 samples were removed due to low technical quality, or 114 missing metadata (age and BMI) leaving the dataset with a total of 1859 proteomic samples from BASE-II participants. After this preprocessing, the final dataset quantified 2079 115 116 proteotypic peptides derived from 248 protein groups (Table S1).

117

Variable	Young (N=426)	Old $(N=1433)$
Age in years [median (IQR)]	28.9 [4.5]	68.8 [5.4]
Sex (N, Women in %)	226 (55)	742 (52)
BMI (N, %)		
Underweight $(BMI < 18.5)$	29(7)	6(0.4)
Healthy $(18.5 \le BMI < 25)$	278(67.3)	508(35.6)
Overweight $(25 \le BMI < 30)$	81 (19.6)	644 (45.1)
Obese (BMI $\geq 30$ )	25(6.1)	269(18.9)
HCU (N, % women)	90(38.5)	
Smoker (N, %)		
Never	214 (50.2)	682 (47.7)
Former $(> 1 \text{ year})$	64(15.0)	597(41.8)
Former $(< 1 \text{ year})$	15 (3.5)	12 (0.8)
Current	133 (31.2)	138 (9.7)
Diabetes (N, %)	1 (0.002)	177 (12.7)
Metabolic Syndrome (N, %)	31 (7.3)	508 (35.9)
Alcohol intake (N, %)		
Occasional ( $\leq 1.3 \text{ g/day}$ )	60(14.2)	154(11.2)
Low Volume $(1.3 < X \le 30 \text{ g/day})$	334(79.2)	1020(74.1)
Excessive $(> 30 \text{ g/day})$	28(6.6)	202(14.7)
<b>MHT</b> (N, %)		
Never		295 (42.8)
Completed		359(52.1)
Ongoing		35(5.1)

Table 1: Study Demographics of study participants subjected to the analysis stratified by age groups. HCU: Hormonal Contraceptive Use, MHT: Menopause Hormone Replacement Therapy

118

119

We calculated a median coefficient of variation (CV) of protein quantities of 12.74 % in study pools and 10.89 % for serum controls samples (Zen-Bio). Reflecting the biological signal, protein quantities in study samples deviated from the technical controls (CV of 27.79 %; Table S1)). While most of the proteins are normally distributed, some proteins, such as lipoprotein (a) (Lp(a)) and complement factor H-related protein 1 (CFHR1), exhibited tailed or almost bimodal distributions (Figures S59, S158). Tailed distributions in certain proteins, particularly

pronounced among the younger age group, were found for proteins that we recently associated to the intake of hormonal contraceptives in younger women (including angiotensinogen (AGT), fetuin B (FETUB), sex hormone binding globulin (SHBG), plasminogen (PLG) or peptidoglycan recognition protein 2 (PGLYRP2))<sup>21</sup>. (Figures S2 - S254 for Log2 transformed protein abundance distributions of all proteins across the entire cohort, as well as stratified by age groups).

132

133 We analyzed functional groups, such as immunoglobulins, coagulation factors, acute-phase 134 proteins, complement factors and lipid transport proteins for their variation. Immunoglobulins 135 (N = 60 protein groups) had the highest median relative variation (CV 44.3 %, range: 23.6 -264.8 %), and included the proteins with the highest individual relative CVs such as IGHV3-136 11 (264.8 %), IGHV3-21 (183.3 %) and IGLV4-60 (150.6 %). In contrast, proteins involved in 137 138 the complement system (N = 36) exhibited lower variation (median CV: 18.4 %, range: 10 -139 63.5 %), including some of the least variable proteins such as the two central mediators of the 140 component system C5 and C3 (both 10.4%). Proteins related to coagulation (N = 30), lipid 141 transport (N = 20) and acute-phase response (N = 26), showed CVs of 19.6 % (range: 11.5%142 - 138.2%), 23.5% (12.9 % -102%) and 22% (10.4% - 262.6%). Besides IGHV3-11, serum 143 amyloid A1 (SAA1; 262.6%) and the pregnancy zone protein (PZP, 225.1%) showed the 144 highest variation in the study samples, while hemopexin (HPX, 9.2%), complement factor 1R 145 (C1R, 10%) and attractin (ATRN, 10.2%) the lowest. CVs for study samples, pooled study 146 samples and QC samples are shown in Tables S3-S5. Furthermore, a detailed functional 147 analysis of the proteins in the dataset is provided in Table S2.

148

149 Next, we conducted a correlation analysis between the values obtained with routinely applied 150 biomarker assays and the corresponding protein abundance levels. For interpreting these 151 results, it is important to keep in mind that proteomics and the diagnostic tests are typically 152 targeting related but not identical analytes. We obtained significant correlations, displayed as 153 spearman's rho if not described otherwise, between proteomics and biomarker assays for 154 apolipoprotein A1 levels (0.67) and B (0.72), low density lipoproteins (LDL) with APOB (0.72) 155 and high-density lipoproteins (HDL) with APOA1 (0.66). Triglyceride measurements showed a moderate correlation with APOC3 levels (0.44). In contrast, diagnostic assays and protein 156 157 abundance determined by proteomics correlated weekly for albumin (0.32), hemoglobin with 158 the MS acquired hemoglobin subunit alpha 2 (HBA2; 0.31), and for fibrinogen compared to 159 fibrinogen alpha chain levels (0.15). Notably, routine test sex hormone binding globulin 160 (SHBG) measurements (prior to log2 transformation) displayed a robust, albeit not strictly 161 linear relationship, with proteomic data (Kendall's tau: 0.61, see Figure S250h). The diverging 162 results show that proteomic measurements provide complementary data to establish 163 diagnostic assays (see Figure S250).

164

## Hormonal contraceptive usage (HCU) is a dominating covariate affecting the serum proteome in young women

167

168 We investigated the effect of demographic covariates, such as sex, age, BMI, and HCU due

to previous findings <sup>21</sup> on the serum proteome of the 1890 BASE-II participants of both age

170 groups by fitting multiple linear regression models to the protein abundance data. In our

analysis BMI was treated as a categorical variable comparing underweight (U, BMI < 18.5),

172overweight (Or,  $25 < BMI \le 30$ ) and obese (Ob, BMI > 30) participants to those with a173healthy BMI (18.5 < BMI  $\le 25$ ). This categorization was chosen because these groups have174higher clinical relevance than the actual, numerical BMI value and are commonly used in175clinical studies. Besides the significance level of 0.05, we also required the abundance176difference of the protein to be higher than the CV of the pooled study samples. Statistical177summaries of the association analysis for the entire cohort and separated by age groups are

- 178 reported inTables S3-S5.
- 179

180 We found 106 protein groups associated with age. Of these, 65 have also been identified as age-dependent in orthogonal studies <sup>21-30</sup>. Among the 41 new associations identified, 32 were 181 182 immunoglobulin chains. Other newly found age-associated proteins include serum amyloid A4 183 (SAA4), proteoglycan 4 and the two platelet-related serum proteins, platelet factor 4 variant 1 184 (PF4V1) and pro-platelet basic protein (PPBP). Amongst the group of age-associated proteins, 185 we report the strongest negative association, with up to 20% abundance change in 10 years, for serpin family F member 2 (SERPINF2), immunoglobulin delta heavy chain (P0DOX3) and 186 187 transferrin (TF). Highest increase with progressing age was found in complement component 188 5 (C5), apolipoprotein B (APOB) and lumican (LUM).


189

190 The above defined age-related differences in the proteome were in part sex dependent, with 191 23 proteins showing a different age-response in male and female study participants. We 192 detected the highest significant differences between men and women in the pregnancy zone 193 protein (PZP), glycosylphosphatidylinositol specific phospholipase D1 (GPLD1), complement 194 component 6 (C6), adiponectin (ADIPOQ) and ceruloplasmin (CP). None of the proteins 195 investigated were associated with an underweight BMI, however, 19 proteins were linked to 196 overweight and obesity, respectively, with APOC2 and fibulin 1 (FBLN1) showing novel 197 associations with elevated BMI <sup>21,43-47</sup>.

198

199 We found new associations with HCU in 15 out of 55 proteins that had not been reported in 200 the related studies before <sup>21,48–50</sup>, such as the phospholipid transfer protein (PLTP), monocyte 201 differentiation antigen (CD14), alpha-1-antichymotrypsin (SERPINA3) and the coagulation 202 factor V (F5) (see Figure 2). Among all covariates, highest effect sizes and significance were 203 reported for HCU (see Figure 1D) with the top 5 candidates being angiotensinogen (AGT), 204 peptidoglycan recognition protein 2 (PGLYRP2), serpin family A member 6 (SERPINA6), 205 fetuin B (FETUB) and ceruloplasmin (CP). We recently investigated the plasma proteomes of 3,472 participants from the CHRIS cohort <sup>21,51</sup>, an Alpine population study examining the 206 207 genetic and molecular backgrounds influencing the incidence and progression of common 208 chronic diseases. To validate our previous findings and demonstrate reproducibility, we 209 compared the effect sizes for age, sex, and BMI categories for the overlapping proteome from the BASE-II analysis with those obtained from a similarly conducted association analysis of 210 211 the CHRIS dataset, both measured on similar mass spectrometry platforms. We observed 212 high concordance: age (Spearman's rho: 0.69), sex (0.85), BMI (obese category: 0.73), and 213 HCU (0.9) (see Figures S256). However, the effect sizes for the underweight BMI category 214 showed a low correlation between the studies (-0.25). Among the 125 overlapping proteins 215 identified in both proteomic datasets, we found 53 proteins to be age-dependent and 13 216 proteins to be sex-dependent in both studies. The age-associated proteins include various functional groups involved in disease pathology, such as components of the complement 217 218 cascade (C5, C7, C9, C4A, C4BPA, C1, CFD, CFI), apolipoproteins (APOB, APOC3, APOD, 219 APOE, APOH), and proteins involved in blood clotting, including coagulation factors X (F10)







222

223

224 225 Figure 2: Multiple linear regression was employed to identify significant protein associations 226 with hormonal contraceptive use (HCU), age, sex and different BMI categories (U: 227 Underweight, Ov: Overweight, Ob: Obese). (A) The impact of HCU on the serum proteome. 228 Proteins with largest coefficients and highest significance (in negative log10 adjusted pvalues) for proteins with use of hormonal contraceptives. (B) The impact of 10-years of aging 229 230 on the serum proteome. (C) The impact of sex (men vs. women) on the plasma proteome in 231 Base-II. Proteins of significance are highlighted in red, and gene names are annotated for 232 those discussed in the text. (D) Proteins associated with the different BMI categories 233 (heatmap). Black dots denote significant associations after multiple testing corrections, while 234 color indicates effect size by its coefficient. 235

#### Lifestyle factors show strong associations with apolipoproteins 236 and inflammation markers in the serum proteome 237

238

239 Building on existing knowledge of lifestyle factors impacting the serum proteome<sup>52</sup>, we investigated the effects of smoking habits, alcohol consumption, diabetes mellitus type 2 240 (T2DM), or metabolic syndrome (metS) on protein abundance as covariates in our multiple 241 242 regression models in addition to age, sex, BMI and HCU. We only included HCU as a 243 covariate in the younger age group. Adjusted p-values, coefficients and effect sizes obtained 244 from the regression analyses of significantly associated proteins with lifestyle factors and

comorbidities are reported in Tables S8 - S12. On this basis we addressed the association of
 selected individual lifestyle factors, i.e. smoking or alcohol consumption, with the serum
 proteome.

248


First, we addressed proteomic changes in current and former smokers. No significantly 249 250 regulated proteins were found in former smokers that guit smoking more than a year ago. On the other hand, older participants who recently guit smoking (less than a year) had a 251 252 significantly elevated level of polymeric immunoglobulin receptor (PIGR), which was also true 253 for current smokers compared to participants who had never smoked (n = 896, see Figure 254 3B). Additionally, immunoglobulin heavy constant gamma 2 (IGHG2) levels were significantly decreased in current smokers from the older age group. IGHG2 levels were also found 255 lowered in the younger group, albeit not significant. Alcohol consumption of the participants 256 257 was grouped into occasional (< 1.3 g/day), low volume and excessive drinkers (>30 g/day) 258 based on their self-reported habits. Among the 8 significantly associated proteins, the most 259 changes were obtained for apolipoprotein C3 (APOC3) and thyroxine-binding globulin 260 (SERPINA7) (see Figure 3C). Both proteins were significantly changed in low volume and 261 excessive drinkers compared to participants that only occasionally drink alcohol, though 262 significance increased with age.

263

Next, we continued to address protein associations with metS in the entire cohort and type 2 diabetes in the older group. The abundance levels of four different apolipoproteins were found to be significantly associated with metS. Specifically, apolipoprotein D (APOD) and apolipoprotein A1 (APOA1) were decreased in participants diagnosed with metS, whereas apolipoprotein C2 (APOC2), and apolipoprotein C4 (APOC4) were increased (see Table S8).

270 Visceral fat accumulation is a key feature of metabolic syndrome and T2DM <sup>53,54</sup>. We analyzed 271 BMI-associated proteins in "overweight" and "obese" categories, considering T2DM and/or 272 metabolic syndrome (metS) as covariates. Without lifestyle factors, 19 proteins were linked to 273 "overweight" and/or "obese"BMI categories (see Table S3). Including T2DM as a covariate, 274 dopamine-beta hydroxylase (DBH) was significantly associated with "obese". In regression analyses with T2DM or metS, PGLYRP2 <sup>56</sup>, SERPINA10 <sup>57</sup>, and LYZ <sup>58</sup> were significant in 275 both elevated BMI categories, which aligns with current literature. Fibulin 1 (FBLN1) remained 276 277 significantly associated (p < 0.05) with both BMI categories, irrespective of covariates. The 278 link between BMI and angiogenesis inhibitor FBLN1 downregulation has not been previously 279 observed. Among the older participants N = 177, or 9.58% of all participants, were diagnosed 280 with T2DM. This prevalence aligns closely with the previously reported rate of 9.9% for T2DM in Germany <sup>62</sup>, based on statutory insurance data <sup>63</sup>. Multiple linear regression analysis 281 282 revealed a positive, significant association of APOA4 with T2DM. In an analysis of 539 participants diagnosed with metS, including some T2DM diagnosed participants, APOA4 (see 283 284 Figure 3A) again emerged as the only significant protein whose variance exceeded technical 285 variability when assessing biomarkers for T2DM.

286



287

**Figure 3:** (A) Increased APOA4 abundance with age and with diabetes mellitus type II (T2DM) (B) Effect of smoking on the PIGR abundance levels. Coefficients and adjusted log10 p-values for the proteomic profiles across different participant groups (Volcano Plot) (C). Proteins significantly associated with alcohol consumption are marked in red and their gene names are annotated. Accompanying split violin plots depict decreasing SERPINA7 (D) and increasing APOC3 (E) levels in BASE-II participants with increasing alcohol consumption. Boxes in violin plots denote the 25% and 75% quantiles, and the median is displayed by a white line.

295 296

297 Considering the established association between metS and T2DM, we performed multiple 298 regression analysis on the complete cohort by including for metS and T2DM as covariates

<sup>64,65</sup>. The only protein that could exceed the technical threshold when both diseases are
 considered as covariates was APOB, which had a significant, positive association with metS
 but did not show a significant one for diabetes.

302

### 303 Impact of menopausal hormone therapy on the high abundant serum proteome

304

305 We recently reported that HCU has a major impact on the high abundant fraction of the plasma proteome, in women under 40 years enrolled in the CHRIS study<sup>21</sup>, and as aforementioned, 306 307 we detected a similar signature in the young women within the BASE-II cohort. With the focus on aging, we herein explored the effect of menopausal hormonal replacement therapy (MHT) 308 309 in older women participating in the BASE-II. For this, we categorized the BASE-II women from the older group (N = 689, aged 61-84) into three groups: those who never underwent MHT 310 (never, N = 295), those who completed MHT (completed, N = 359) and those who underwent 311 312 treatment at sampling time (*ongoing*, N = 35). Only study participants with documented start 313 and/or termination of MHT were considered. The median treatment duration for the MHT 314 completed group was 11 years (IQR 8 years), and for the ongoing group, it was 18 years (IQR 315 9 years), reflecting a later onset of menopause <sup>70</sup>. Subsequently, we employed multiple 316 regression models incorporating age, BMI, and a categorical variable denoting MHT status to 317 evaluate associations between protein abundances and the treatment.

318

We identified three proteins - angiotensinogen (AGT)<sup>71–74</sup>, peptidoglycan recognition protein 2 (PGLYRP2)<sup>75</sup> and plasminogen (PLG) - to be significantly changed between study participants that are currently undergoing MHT treatment and those who have never received treatment. Additionally, we observed non-significant upregulation of ceruloplasmin (CP) and nonsignificant downregulation of vitamin K-dependent protein S (PROS1), C4b-binding protein alpha chain (C4BPA), lumican (LUM), and complement component 8A (C8A with MHT in our analysis.


326

327 Next, we investigated the predictive power of the serum proteome for classifying MHT status 328 of the female BASE-II participants based on the serum proteome to enhance understanding 329 of the underlying biological processes affected by hormonal treatments and add to already 330 available literature concerning treatment effects on the serum proteome. We first matched 331 female study participants under ongoing treatment (N = 35) to an equally sized control group 332 by age and BMI based on propensity scores acquired from a generalized linear model <sup>76</sup> (Age 333 and BMI demographics are listed in Table S7). Next, we selected plasminogen (PLG) and complement component 9 (C9) as the most informative features by a cross-validated, 334 recursive feature elimination process<sup>77</sup>. We then trained a random forest <sup>78</sup> in a 5-Fold cross 335 336 validation stratified by MHT status. The two-protein classifier achieved a mean test data area 337 under the curve (AUC) of 0.82, comparable to the AUC of 0.80 for individual estradiol levels, the active ingredient in most MHT. Moreover, since a training AUC of 0.84 was obtained, the 338 339 classifier should be robust against overfitting. ROC curves for different splits in the CV 340 procedure can be found in Figure S258. Other hormones such as SHBG or testosterone were 341 outperformed by the random forest predictor (Figure S259). To get a better understanding of 342 the decision boundaries of the two proteins in the random forest classifier we predicted 343 decision probabilities for the range of observed PLG and C9 fold changes (FC) to the log2

344 median abundance values (Figure 5B). The highest predictive probability for ongoing MHT 345 was at PLG at FC above 0.2 and C9 log2 FCs below -0.1 or above 0.4, although the latter has to be interpreted with caution since it is not well displayed in our data. Conversely, we expect 346 347 the highest predictive power for no MHT at PLG levels below 0.2 and C9 levels between -0.1 348 and 0.4. Ensemble models that rely on multiple weak learners rarely produce predicted 349 probabilities close to 0 or 1 because it requires all the individual models to make the same 350 decision. This is particularly unlikely in random forests due to the bootstrapping (random 351 sampling with replacement) used to create each individual tree 79.

352





354 355

Figure 4: Machine learning classifier based on Complement Component 9 (C9) and 356 357 Plasminogen (PLG) abundance levels slightly outperforms serum estradiol levels in predicting 358 MHT status (A) Receiver operating characteristic (ROC) curve shows predictive performance of single parameter models with estradiol (coloured in gray), C9 (blue), PLG (orange) and the 359 360 two protein random forest model (C9 + PLG) (red) predicting current hormonal treatment. (B) 361 Contour plot depicting the predictive probability generated by the random forest classifier 362 based on C9 and PLG levels. The areas highlighted in red represent the abundance ranges of PLG and C9, which support the classification of participants undergoing MHT. The added 363 dots display the protein abundance measurements with participants currently under hormonal 364 treatment (red) and controls (blue). Vertical and horizontal color gradations show cut-offs of 365 the individual decision trees in the random forest model. Axis show the log2 FC to the median 366 367 abundance of PLG (y) and C9 (x).

368

#### 369 Discussion

Large-scale serum and plasma proteome studies <sup>21,43,80,81</sup> have revealed disease prevalence, 370 371 risk factors, and healthcare needs across diverse populations. These studies have identified putative biomarkers of aging 1,21-24,80, common lifestyle factors like Type II Diabetes, and 372 administered drugs <sup>43,82,83</sup>. Advancing age significantly heightens the risk for various chronic 373 374 ailments alongside physical and cognitive decline, ultimately leading to mortality. 375 Consequently, age directly impacts critical physiological processes, including inflammation <sup>84</sup>, 376 often referred to as 'inflammaging', and cellular senescence <sup>85</sup>. However, biomarkers 377 associated with aging have yet to gain widespread acceptance within the biomedical field,

partly due to the non-trivial nature of validating them <sup>86</sup>. The BASE-II <sup>14</sup> specifically aims to
 explore factors influencing a healthy aging process, presenting a rich resource for further
 investigations of age-related proteins.

381

In this study, mass spectrometry-based serum proteomics of 1859 BASE-II participants 382 383 consistently quantified 2917 peptides from 248 protein groups at high precision. While the 384 number of proteins in this upper fraction of the plasma proteome may seem limited, this group 385 of proteins is secreted in many isoforms and is particularly interesting for biomedicine. 386 Altogether, these proteins account for more than 99% of the plasma's proteomic mass. This 387 high abundant fraction covers many of the currently clinically used protein biomarkers, spans over many targets of FDA approved biomarkers, and closely reflects human physiology. 388 Thereby they cover many functions in the complement system, coagulation, immunoglobulin, 389 and acute-phase response <sup>10,15,87–91</sup>. 390

391

392 Epidemiological covariates such as age, sex and BMI have a considerable impact on the 393 general health of the population, but the mechanisms are multifactorial and complex. It has 394 been shown that progressing age and very low or high BMI can pose a risk factor for multiple disease mechanisms and their progression <sup>92–94</sup>. With the advances of personalized medicine, 395 these factors are important for treatments tailored to individual patients <sup>95</sup>. Specifically, the 396 high abundant serum or plasma proteome that plays a vital role in disease pathology and 397 398 metabolism, has to be investigated for these effects to reveal true relationships of treatment and disease <sup>9–12</sup>. Furthermore, differences in epidemiological factors also pose a technical 399 400 challenge when analyzing proteomic data. Common techniques to address this include 401 balancing or using epidemiological information as covariates in linear (factorial) models <sup>96</sup>. 402

403 Previous proteomic studies into aging cohorts successfully predicted age, mortality, and made attempts to distinguish biological from chronological age ('proteomic clock') 5,22-24,97. The 404 BASE-II design is slightly different to these investigations, as sampling was not continuous 405 406 over the age range, but rather categorical, and sampled from an aged group and a young 407 control. The BASE-II is well annotated with demographic and metadata, which facilitated to 408 probe for association of age with several demographic and physiological factors. Our 409 association analysis did both, confirm proteins that were previously reported as age-410 dependent in the literature, as well as identify new proteins. Indeed, the abundance levels of 411 106 of 248 consistently quantified proteins were changed with age. Of these, 39% (N = 41) 412 were not reported as age-associated in previous datasets <sup>21-30</sup>. Thirty-two of these are 413 immunoglobulin chains, which is consistent that the adaptive immune system changes as we 414 age <sup>98</sup>. We hope our results stimulate future investigations using antigen-capture technologies, 415 to identify the biological targets of these immunoglobulins.

416

417 Furthermore, we report associations to some pathologically highly relevant proteins including 418 the pro-inflammatory serum amyloid A4 (SAA4), which has been linked to various infectious diseases such as malaria or COVID19<sup>99,100</sup> as well as rheumatic inflammation<sup>101</sup>. Another 419 protein identified as age-dependent in our study is proteoglycan 4 (PRG4), which has been 420 associated with tissue regeneration <sup>31</sup> and inflammation regulation <sup>32,33</sup>. It also functions as a 421 422 boundary lubricant at the cartilage surface of joints, which function is known to decrease with progressing age. However, a direct connection to osteoarthritis, which can be caused due to 423 decreased cartilage lubricants <sup>102</sup> are not yet described. In contrast to our findings, a negative 424 regulation of PF4V1 and PPBP with age platelet activity has been described while platelet 425

426 counts were shown to increase with age <sup>103</sup>. Platelet factor 4 variant 1 (PF4V1)<sup>104</sup> has been 427 associated with angiogenesis, which, if pathogenic, can serve as a marker for autoimmune 428 diseases, cancer, and cardiovascular diseases. Additionally, pro-platelet basic protein (PPBP) 429 has been reported to have a wide range of functions, including neutrophil activation and 430 antibacterial activity <sup>105</sup>.

431

432 The sex dependency of the BASE-II proteome aligns well with the results obtained in other cohorts  $^{21,23,34-42}$ . The list of n = 23 sex dependent proteins includes the pregnancy zone 433 protein (PZP), the sex hormone binding globulin (SHBG) and angiotensinogen (AGT). 434 435 Moreover, as we have reported recently, HCU had the strongest impact on the serum proteome of BASE-II participants, with PGLYRP2 being the main suppressed protein, and 436 437 AGT, SERPINA6, FETUB the most induced. We found new HCU associations for 15 proteins, such as the acute-phase protein SERPINA3<sup>106</sup>, the monocyte and macrophage cell surface 438 439 protein CD14<sup>107</sup> and the coagulation Factor 5 (F5).

440

Furthermore, we compared effect sizes for age, sex, BMI, and hormonal contraceptive usage 441 442 with those from our recently presented analysis of the CHRIS dataset <sup>21</sup>. We found correlations 443 of up to 0.9 for HCU (Spearman's rho), indicating a consistent effect on the plasma and serum 444 proteome across both studies. Found age-associated proteins (N=53) in both studies included 445 various components of the complement system (N=8) and apolipoproteins (5). Hence, the previously described age association of these mechanisms aligns with our results <sup>36,109,111–113</sup>. 446 447 The most prominent sex-dependent proteins in both the CHRIS and BASE-II proteomic 448 datasets include SHBG, which is recognized as a key proteomic marker for sex differences, 449 complement component 6 (C6), TTR, and ceruloplasmin (CP). Effect sizes for underweight 450 BMI showed a negative correlation (-0.25), likely due to the small number of participants in 451 this category (N=35), resulting in less consistent results.

452

453 We also addressed the role of body weight which is linked to various comorbidities <sup>114</sup>. We did not find significant associations with underweight, which was most likely caused by the low 454 sample size and hence lower statistical power. Similar to previous studies<sup>115</sup>, we detected an 455 association of apolipoproteins D and M levels with elevated BMI. We also report novel protein 456 associations with BMI including Apolipoprotein C2 (APOC2) and fibulin 1 (FBLN1), when 457 458 corrected for metabolic disorders such as T2DM and metS. When both metabolic conditions 459 (metS and T2DM) are considered as covariates, C5 emerges as a significantly upregulated protein in obese patients. This could be due to its role in regulating inflammation in adipose 460 tissue <sup>116</sup>, but also aligns well with our report, that the complement system is BMI dependent 461 462 <sup>117</sup>. Interestingly, this association is sensitive to metS and T2DM, which suggests that the onset of metabolic disease influences the complement system. Similarly, FN1 <sup>118</sup>, VWF <sup>119</sup>, 463 ECM1 <sup>120</sup>, and ADAMTS13 <sup>121</sup> are only significantly downregulated in obese and overweight 464 patients when metS and T2DM are included as covariates. Furthermore, we found DBH 465 significantly associated with "obese" BMI, when adjusted for T2DM in the older group of 466 467 participants, aligning with prior findings in DBH-deficient mice <sup>55</sup>.

468
469 BASE-II offers a valuable insight into proteomic signatures of metabolic disease like metS and
470 T2DM as the incidence within our cohort aligns with previously reported national numbers
471 <sup>63,122,123</sup>. Our findings indicate that lifestyle factors like T2DM and metS diagnosis, influence

the serum proteome to varying extents across different age groups. Notably, apolipoprotein
A4 (APOA4) was significantly upregulated in T2DM cases, particularly when metS was
considered. APOA4, primarily synthesized in the small intestine, is crucial for lipid

475 metabolism, insulin sensitivity, and food intake regulation. Elevated APOA4 levels are also 476 markers for kidney disease progression and diabetic nephropathy, <sup>124</sup> highlighting its potential 477 as a marker for T2DM monitoring and prognosis. Significant associations were also found 478 between metS and various apolipoproteins, including C2, C4, B, and D. Apolipoprotein D 479 (APOD) was consistently downregulated, especially in the older cohort. APOD, involved in lipid trafficking and neuroprotection, enhances insulin sensitivity and metabolic health<sup>125</sup> but is 480 often reduced in metS patients, correlating with hyperchylomicronemia<sup>126</sup>, characterized by 481 increased triglyceride and chylomicron levels in blood and dysfunctional APOD in metS<sup>127</sup>. 482 483 Notably, this downregulation was more pronounced among older metS patients, potentially reflecting an age-related increase in APOD expression <sup>128</sup>. APOC2 <sup>52</sup> and APOC4, part of a 484 485 gene cluster including APOE <sup>129</sup>, are implicated in metabolic regulation. While APOE, a known 486 marker of metabolic syndrome, was not significantly associated with metS in our study, 487 APOC4 was upregulated in both age groups. APOC2 and APOC4 play pivotal roles in lipid 488 metabolism and triglyceride processing associated with very low-density lipoprotein (VLDL) <sup>129,130</sup>. Although the literature does not establish a direct link between APOC4 and metS, its 489 490 role in lipid metabolism supports a potential relationship with metS and other cardiometabolic 491 diseases. Prior research has also associated an increase in serum APOC2 levels with a diagnosis of metS <sup>52</sup>. APOB serves as a clinical marker of atherosclerosis due to its 492 association with low-density lipoprotein (LDL) and is an independent predictor of metS 493 development <sup>127,131</sup>. Previous research has shown that the clinical value of APOB in predicting 494 495 metS is maintained even after accounting for the comorbidities linked with it <sup>127,132</sup>. Our results 496 further corroborate these findings, with significant upregulation of APOB in both age groups. 497 Recent studies have highlighted the critical role of the apolipoprotein protein family in regulating triglycerides (TGs) and cholesterol metabolism, transport, and cellular management 498 499 <sup>133</sup>. These findings are consistent with our observations of deregulated apolipoprotein family 500 members in metabolic diseases, underscoring their significance as potential therapeutic and 501 diagnostic targets. APOB was the sole protein for which the abundance change associated 502 with disease surpassed the technical threshold in the regression analysis that considered both T2DM and metS. Serum APOB levels are directly linked to insulin secretion <sup>134</sup>, where 503 504 decreased insulin sensitivity is associated with increased secretion and decreased clearance 505 of APOB. Prediabetes, characterized by visceral fat accumulation and impaired insulin sensitivity, is considered an underlying condition of metS<sup>135</sup>. The strong link between metS 506 507 and T2DM has been established in relation to both incidence and the molecular mechanisms underlying their prognosis <sup>64,65</sup>. Notably, administering oral antidiabetic drugs such as 508 509 dipeptidyl peptidase-4 inhibitors (DPP4i) in T2DM patients was associated with reduced plasma APOB levels <sup>66</sup>. Among the participants diagnosed with T2DM, 85 were receiving orally 510 511 administered blood glucose-lowering drugs excluding insulin, which indicates the potential 512 utility of APOB in monitoring treatment outcomes. Our study revealed a novel link between 513 serum fibulin 1 (FBLN1) levels and higher BMI categories. FBLN1, a regulatory component of 514 the extracellular matrix, is downregulated in higher BMI categories, indicating potential disruptions in cellular homeostasis, mobility, and adhesion <sup>138,139</sup>. Markers of chronic 515 516 inflammation and cellular degeneration such as lysozyme (LYZ) and alpha-2-macroglobulin (A2M) were also associated with individuals belonging to the "overweight" and "obese" 517 518 categories, but these associations disappeared when adjusting for T2DM and metS. Only

519 FBLN1 remained significantly linked to BMI, indicating its potential as a robust biomarker, 520 regardless of T2DM or metS.

521

522 Lifestyle factors are modifiers of the blood protein profile. Plasma/serum proteomics might 523 thus be able to complement patient questionnaires in clinical studies, as these have the reputation to be unreliable, specifically, when they address guestions related to stigmatized 524 lifestyle components, such as alcohol consumption or smoking <sup>140</sup>. One notable marker for 525 current and former smoking habits identified in our analysis was an increased abundance of 526 PIGR in smokers. PIGR transports IgA through mucosal epithelia,<sup>140</sup> and has been linked to 527 smoking previously <sup>141,142</sup>. In contrast to previous studies, we also report higher PIGR levels 528 529 in some former smokers, specifically older participants who quit recently (less than a year) <sup>143</sup>. 530 Although imprecise responses about smoking habits in the questionnaires might partly explain 531 these results (e.g., some individuals who identified as ex-smokers might still be smoking), the 532 findings could also suggest that some individuals experience a longer recovery time from 533 smoking-related chronic inflammation. Similarly, downregulation of IGGs, specifically IGHG2, relates to smoke-related inflammation <sup>143,144</sup>. Our observations reinforce the idea of pulmonary 534 inflammation as a consequence of smoking, which we show, might be traceable even in former 535 536 smokers to a certain degree.

537

Excessive alcohol consumption (defined as more than 30 g/day) led to deregulated serum
levels of several key metabolic proteins. The two with the highest significance, APOC3 and
SERPINA7, were respectively upregulated and downregulated.

541 Increased APOC3 levels with increased alcohol consumption have been previously observed <sup>145,146</sup> and decreased serum thyroxine as well as SERPINA7 levels have been linked to 542 alcoholism <sup>147</sup>. APOC3, a major HDL component released from hepatocytes, influences 543 544 triglyceride catabolism and is associated with ethanol consumption, decreasing after alcohol withdrawal <sup>148,149</sup>. Alcohol-induced increases in HDL are attributed to the increased expression 545 of cholesteryl ester transfer protein in response to ethanol intake<sup>150</sup>. On the other hand, 546 547 SERPINA7 was downregulated in excessive drinkers, a phenomenon observed in the context 548 of the gut-thyroid axis <sup>151,152</sup>. This observation could be attributed to liver dysfunction due to 549 overworking, which impairs the liver's ability to effectively synthesize SERPINA7<sup>153</sup>.

550

551 Eventually, we investigated the influence of MHT on the data subset of women from the older age group in the BASE-II. Statistical significant associations with MHT were found for 552 553 peptidoglycan recognition protein 2 (PGLYRP2), angiotensinogen (AGT) and plasminogen 554 (PLG), which have been described before to be influenced by estradiol-based hormone therapy or medication, such as hormonal contraceptives <sup>21,71,154,155</sup>. Eight other proteins 555 556 <sup>74,75,156,157</sup> showed trends similar to those described in the literature but did not reach 557 significance levels. However, while other studies reported the dysregulation of Lp(A), APOA 558 and APOB <sup>158,159</sup>, these proteins were not identified in our analysis (Figure S257 and Table 559 S6). Furthermore, no protein was found significant between women with previous MHT treatment and those that never received treatment. Thus, in our dataset, we did not find any 560 significant long lasting changes in the plasma proteome by MHT. The impact of MHT on the 561 562 proteome (with N = 3 significant protein associations) compared to HCU (with N = 55) aligns 563 well with the lower dosage of estradiol in MHT and the predominant use of bioidentical estradiol as an active ingredient in MHT compared to classical HCU, which predominantly 564 565 contains the more powerful synthetic ethinylestradiol and much higher dosages. Employing

566 machine learning, we successfully differentiated between participants who had undergone 567 MHT during sampling from those who had not, achieving an AUROC of 0.82%. Interestingly, 568 we obtained best separation with a random forest model trained solely on abundance levels 569 of PLG and C9, which were identified beforehand in a recursive feature elimination process, 570 even slightly outperforming the predictive performance of estradiol (AUROC: 0.8), a major 571 component of most used MHTs.

572

#### 573 Conclusion

574

575 In summary, our study reports a significant serum proteome remodeling during aging. Our data confirms previous, and reports new associations, of serum proteins that change during 576 577 aging dependent on age, sex, and BMI, and highlights the influence of lifestyle factors such 578 as smoking and alcohol consumption. In particular, our findings underscore the impact of 579 hormonal therapies, HCU in young female study participants, and MHT in older female 580 participants, which both have a quantitative impact on the serum proteome. Especially HCU 581 had a stronger impact than any other covariates on the serum proteome in the younger female 582 participants. Our study did not assess whether the proteomic changes resulting from HCU or 583 MHT are related to health outcomes. We hope however our study will stimulate studies to 584 clarify this question. Overall, our findings provide valuable insights into the factors influencing serum proteome remodeling during aging and pave the way for future research to explore the 585 586 health implications and potential therapeutic interventions.

587

#### 588 Limitations

589

590 The study design includes two distinct age groups (27-37 and 60-84 years) and therefore we 591 cannot claim to ultimately depict effects between these age ranges. However the high overlap of age-associated proteins between our analysis and comparable studies <sup>21-24</sup> implies that our 592 593 analysis is reliable. The analysis of MHT effects is based on a relatively small sample size of 594 positive cases (N = 35). To minimize adverse effects as much as possible, we therefore 595 matched the treatment group to a control group with comparable age and BMI. The small sample size also limits an analysis of admission routes and active drug ingredients (Gestagen 596 597 and Estrogen) of MHT. But we report this information, for future reference in the supplement 598 (see Figure S260). Another potential limitation of our study is the categorization of alcohol consumption based on self-reported daily intake. Although we used the same thresholds for 599 both men and women as cited in previous studies <sup>160–162</sup> (see Methods), the German Center 600 601 for Addiction Issues (DHS) defines low-risk alcohol consumption differently for women (<12 g/day) and men (<24 g/day)<sup>163</sup>. These differing limits complicated the definition of a moderate 602 alcohol consumption group and led to a larger portion of the cohort being classified as 603 excessive drinkers. Given the distribution of age and sex among participants as well as known 604 605 clinical details about the group, which were also covariates in our analysis, we chose to define 606 alcohol consumption limits based on established studies.

- 607
- 608
- 609
- 610

#### 611 Methods

- 612 Berlin Aging Study II
- 613

614 Berlin Aging Study II (BASE-II) participants were recruited from the greater metropolitan area of Berlin, Germany. The multidisciplinary BASE-II aims to identify mechanisms and factors 615 616 contributing to healthy vs unhealthy aging. In total 1.671 older participants (aged  $\geq 60$  years) and 500 younger (20-37 years) were assessed in the medical part of the study at baseline 617 between 2009 and 2014<sup>14</sup>. The medical assessments were conducted in accordance with the 618 619 Declaration of Helsinki and approved by the Ethics Committee of the Charité -620 Universitätsmedizin Berlin (approval number EA2/029/09) and were registered in the German 621 Clinical Trials Registry as DRKS00009277. Blood was drawn from all participants after an >8h fasting period and kept at 4-8 °C until analysis on the same day or was stored at -80 °C 622 (serum, plasma). Estradiol, total testosterone, and sex hormone-binding globulin (SHBG) were 623 624 measured in serum probes by fluoro-, radio- and electrochemiluminescence immunoassays by an accredited laboratory. Standard laboratory parameters (including estradiol, testosterone 625 626 and SHBG) and proteome analyses were performed on blood from the same draw. Smoking 627 behavior (current smoker, former smoker, never smoker), hormonal contraceptive usage and 628 menopause hormone replacement therapy were assessed during the 1:1 interview by trained 629 study personnel. Alcohol consumption was assessed in g/day via food frequency auestionnaire <sup>164</sup>. Body Mass Index (BMI, kg/m2) was calculated from height and weight 630 measured with an electronic measuring station (seca 763 measuring station, SECA, 631 632 Germany). Diabetes mellitus type 2 was diagnosed based on American Diabetes Association 633 (ADA) guidelines <sup>165</sup>, and the metabolic syndrome was diagnosed according to Alberti et al. 166 634

#### 635 Sample Preparation

641

In this study, a total of 2,191 samples were subjected to measurement. Among these, 105
standardized, commercially available serum set samples (SER-SPL, Zen-Bio, Durham, NC,
USA) and 96 were pooled study samples that were utilized to monitor measurement quality
and control technical variation. Measurements were performed in 8 batches, each consisting
of 3 96-well plates. Serum samples were randomly distributed across all plates.

642 Semi-automated in-solution digestion was performed as previously described for high throughput clinical proteomics<sup>15</sup>. All stocks and stock plates were prepared in advance to 643 644 reduce variability and were stored at -80°C until use. Briefly, 5 µl of thawed samples were 645 transferred to the denaturation and reduction solution (55 µl 8 M Urea, 100 mM ammonium bicarbonate (ABC), 5 mM dithiothreitol per well) mixed and incubated at 30°C for 60 minutes. 646 647 Five microliters were then transferred from the iodoacetamide stock solution plate (100 mM) 648 to the sample plate and incubated in the dark at RT for 30 minutes before dilution with 100 649 mM ABC buffer (340 µl). 220 µl of this solution was transferred to the pre-made trypsin stock 650 solution plate (12.5 µl, 0.1 µg/µl) and incubated at 37°C for 17 h (Benchmark Scientific Incu-651 Mixer MP4). The digestion was quenched by addition of formic acid (10% v/v, 25 µl) and 652 cleaned using C18 solid phase extraction in 96-well plates (BioPureSPE Macro 96-Well, 100 mg PROTO C18, The Nest Group). The eluent was dried under vacuum and reconstituted in 653 654 60 µl 0.1% formic acid. Insoluble particles were removed by centrifugation and the samples 655 transferred to a new plate.

#### 656 Liquid Chromatography and Mass Spectrometry

657 Digested Peptides were analyzed on a Bruker timsTOF Pro mass spectrometer coupled to a 658 Bruker VIP-HESI electrospray source. Chromatographic separation was performed on the 659 same column type but with only 2 µg and a flow rate of 500 µL/min. For diaPASEF acquisition <sup>167</sup>, the electrospray source was operated at 3000 V of capillary voltage, a drying gas flow rate 660 of 10 L/min and 240 °C. The diaPASEF windows scheme was set up as followed: we sampled 661 an The ion mobility range was sampled from 1/K0 = 1.30 to 0.7 Vs/cm2 using ion accumulation 662 663 times of 100ms and ramp times of 133ms in the dual TIMS analyzer, with each cycle times of 1.25 s. The collision energy was lowered as a function of increasing ion mobility from 59 eV 664 at 1/K0 = 1.6 Vs/cm<sup>2</sup> to 20 eV at 1/K0 = 0.6 Vs/cm<sup>2</sup>2. For all experiments. TIMS elution 665 voltages were calibrated linearly to obtain the reduced ion mobility coefficients (1/K0) using 666 three Agilent ESI-L Tuning Mix ions (m/z, 1/K0: 622.0289, 0.9848 Vs/cm2; 922.0097, 1.1895 667 668 Vs/cm2: and 1221.9906, 1.3820 Vs/cm2).

669

#### 670 Data processing

Raw MS data was processed using DIA-NN v1.8.1 <sup>19</sup>. DIA-NN mass accuracies and scan window size were fixed to ensure reproducibility (scan window size: 7; MS1/MS2 15 ppm). An external, publicly available spectral library was used for all measurements<sup>20</sup>. The spectral library was annotated using the Human UniProt<sup>168</sup> isoform sequence database (Proteome ID: 3AUP000005640)<sup>20</sup>. It is accessible via the PRIDE database under ID PXD013231.

676

677 All preprocessing steps (including normalization, batch correction and imputation) were 678 performed in the R programming language (v4.3.1). The raw Dia-NN output was imported into 679 R using the *msdap* package<sup>169</sup> and initially filtered for serum set QC samples and non-680 proteotypic peptides (peptides mapping to multiple proteins).

681

682 Subsequently, the dataset underwent cyclic loess normalization<sup>170</sup> to normalize peptide and each other 683 intensities between each sample sample, followed by the 684 'modebetween protein' method that performs the same normalization on a protein level. The 685 normalized data was filtered iteratively to remove samples with too many missing peptide 686 intensities (3 median absolute deviations), followed by the filtration of low-presence peptides 687 measured in less than 30% of all samples. The filtered data was then imputed using Bayesian PCA (bpca) from R's *pcaMethods* package<sup>171</sup>, where the missing peptide intensities were 688 imputed within the same batch, sex (male/female) and age-group combinations (young/old), 689 690 but only for peptides in those combinations which were measured in at least 66% of the 691 samples. Subsequently, batch effects were corrected between all 24 plates using the 692 removeBatchEffect function in the limma Bioconductor package<sup>172</sup>.

693

Finally, any remaining missing values in precursors with less than or equal to 34% missing
values were imputed using the *impute.knn* k-nearest neighbor (knn) algorithm from package
impute version 1.76 <sup>173</sup>, followed by a protein-level summarisation using the function *rcModelPLM* probe-level model (plm) from package preprocessCore version 1.64<sup>174</sup>. The final
dataset after preprocessing consists of 248 proteins and 2917 Peptides for 2079 samples.
However, the number of proteins includes multiple isoforms for Kinogen 1 (2 isoforms, KNG1),
Inter-alpha-trypsin inhibitor heavy chain H4 (2, ITIH4), Gelsolin (2, GSN), alpha-1-B

glycoprotein (2, A1BG) and Fibulin 1 (3, FBLN1). Peptide Sequences for all proteins arereported in Tables S3-S5.

703

#### 704 Statistical Analysis and Machine Learning

705 Functional protein analysis was performed with the PANTHER classification system<sup>175</sup>. 706 Subsequent statistical analysis and machine learning of protein data was conducted in the 707 Python programming language (v3.11), unless specified otherwise. Principal Component 708 Analysis was conducted with standardized protein abundance data by employing the scikit-709 learn package<sup>176</sup>. The arrows added to the plot indicate both the direction and magnitude of 710 the loadings. A significance level of alpha <= 0.05 was employed and p-values were adjusted 711 by bonferroni. Additionally, we employed a second significance criteria to account for technical 712 variance, by comparing the coefficient of categorical covariates as a percentage to the CV of 713 the study pools. We excluded 30 samples due to missing age or BMI information and one 714 sample due to a duplicated measurement. Linear models, as implemented in statsmodels<sup>177</sup> 715 ordinary least squares (OLS) function, were fitted to the log2 protein abundance of all proteins 716 to investigate associations. Age was treated as a continuous variable and divided by 10, thus 717 the age-related coefficients show the change in 10 years difference. All other variables used 718 in the association analysis were treated as categorical variables and were assigned a fixed 719 reference category. For linear modeling, defined the BMI category "healthy" (18.5 < BMI  $\leq$  25; 720 reference) as the baseline level and obtained coefficients for the contrast with "underweight" 721 (BMI < 18.5), "overweight" ( $25 < BMI \le 30$ ) and "obese" (BMI > 30). Smoking was also 722 categorized in 4 groups, such as never smoked (never), stopped more than a year ago (former 723 > 1 year), less than year ago (former < 1 year) and current smokers (current). The alcohol 724 consumption of participants was categorized according to defined ranges in the related 725 literature <sup>160–162</sup>. In these studies, occasional drinking is defined as consuming less than 1.3 g 726 of ethanol per day, low volume drinking is defined as consuming between 1.3 g and 30 g of 727 ethanol per day, and excessive alcohol consumption is defined as consuming more than 30 g 728 of ethanol per day. Furthermore, reference categories for sex, MHT, metS and diabetes were 729 men, never treated with MHT and not diagnosed for metS and diabetes, respectively. 730 Standardized effect sizes (ES) were obtained by subtracting the mean of every protein and 731 dividing through its standard deviation prior to linear modeling. Spearman's rho was used to 732 calculate correlation coefficients as implemented in Scipy<sup>178</sup> if not indicated otherwise. 733 Hormonal contraceptive usage (HCU) was defined as in intake within the last 3 months and 734 considered only oral and not topical administration. Protein CVs for study, pooled and 735 standardized serum set samples can be found in Table S1. CVs were calculated by dividing 736 the standard deviation of the abundance data by its mean and expressed as a percentage.

737

738 Prior to machine learning, we constructed an age and BMI matched control group (N=35) of women that were never treated with any kind of hormonal replacement therapy to ensure a 739 balanced dataset. Matching was conducted by employing R's matchit package<sup>76</sup> with a 740 741 "nearest" matching method and by estimating propensity scores by a "mahalanobis" based 742 distance matrix. Demographics of both, control and treatment group, are shown in Table S7. 743 We employed random forest models to classify women based on their MHT status as implemented in the scikit-learn<sup>176</sup> package. Next, to the best predictive performance compared 744 to other machine learning architectures such as Support Vector machines or boosting 745 746 algorithms, random forests also do not need additional feature scaling and are robust to noise

747 and overfitting due to bootstrapping. To reduce model complexity and only select the most 748 informative features, we employed a cross-validated recursive feature elimination approach 749 (as implemented in scikit-learn) with 10 features removed at every iteration. We finetuned the 750 model using grid search, which constrained the model to have 10 trees and a maximum node 751 depth of 2. Prediction scores were obtained in a 5-Fold cross validation procedure, where training and test sets were balanced by MHT status. To obtain predicted probabilities for 752 Figure 5B, we trained a random forest with identical hyperparameters on all 70 individuals that 753 754 have been used in the cross validation before. The predicted probabilities of random forest 755 models are calculated by dividing the number of votes for a particular class by the total number 756 of trees. Receiver Operating Curves (ROC), the area under the receiver operating curve (AUROC) were calculated with scikit-learn. To evaluate model performance across multiple 757 cross validation sets, we aggregated the false positive rates (FPR) from each test set, creating 758 759 a comprehensive set of unique and sorted FPR values. We then interpolated the true positive 760 rates (TPR) for these FPR values from each test set, averaged the interpolated TPRs, and 761 calculated the mean ROC curve.

762 References

- Moaddel, R. *et al.* Proteomics in aging research: A roadmap to clinical, translational
   research. *Aging Cell* 20, e13325 (2021).
- 765 2. Ping, P. *et al.* A functional annotation of subproteomes in human plasma. *Proteomics* **5**,
- 766 3506–3519 (2005).
- 3. Bader, J. M., Albrecht, V. & Mann, M. MS-Based Proteomics of Body Fluids: The End of
  the Beginning. *Mol. Cell. Proteomics* 22, 100577 (2023).
- 769 4. Rando, T. A. & Jones, D. L. Regeneration, Rejuvenation, and Replacement: Turning
- 770 Back the Clock on Tissue Aging. *Cold Spring Harb. Perspect. Biol.* **13**, (2021).
- 5. Sathyan, S. *et al.* Plasma proteomic profile of age, health span, and all-cause mortality
  in older adults. *Aging Cell* **19**, e13250 (2020).
- Kuo, C.-L. *et al.* Proteomic aging clock (PAC) predicts age-related outcomes in middleaged and older adults. *Aging Cell* e14195 (2024).
- 775 7. Tanaka, T. *et al.* Plasma proteomic signature of age in healthy humans. *Aging Cell* 17,
  776 e12799 (2018).
- 8. Santos-Lozano, A. *et al.* Successful aging: insights from proteome analyses of healthy
  centenarians. *Aging* **12**, 3502–3515 (2020).
- Anderson, N. L. & Anderson, N. G. The human plasma proteome: history, character,
  and diagnostic prospects. *Mol. Cell. Proteomics* 1, 845–867 (2002).
- 781 10. Vernardis, S. I. *et al.* The Impact of Acute Nutritional Interventions on the Plasma
  782 Proteome. *J. Clin. Endocrinol. Metab.* **108**, 2087–2098 (2023).
- 11. Macklin, A., Khan, S. & Kislinger, T. Recent advances in mass spectrometry based
  clinical proteomics: applications to cancer research. *Clin. Proteomics* 17, 17 (2020).
- Hartl, J. *et al.* Quantitative protein biomarker panels: a path to improved clinical practice
  through proteomics. *EMBO Mol. Med.* **15**, e16061 (2023).
- 13. Messner, C. B. et al. Mass spectrometry-based high-throughput proteomics and its role
- in biomedical studies and systems biology. *Proteomics* **23**, e2200013 (2023).

- 14. Bertram, L. et al. Cohort profile: The Berlin Aging Study II (BASE-II). Int. J. Epidemiol.
- **43**, 703–712 (2014).
- 15. Messner, C. B. *et al.* Ultra-High-Throughput Clinical Proteomics Reveals Classifiers of
  COVID-19 Infection. *Cell Syst* **11**, 11–24.e4 (2020).
- 16. Szyrwiel, L., Gille, C., Mülleder, M., Demichev, V. & Ralser, M. Fast proteomics with dia-
- 794 PASEF and analytical flow-rate chromatography. *Proteomics* **24**, e2300100 (2024).
- 795 17. Skowronek, P. & Meier, F. High-Throughput Mass Spectrometry-Based Proteomics with
  796 dia-PASEF. *Methods Mol. Biol.* 2456, 15–27 (2022).
- 18. Kistner, F., Grossmann, J. L., Sinn, L. R. & Demichev, V. QuantUMS: uncertainty
- 798 minimisation enables confident quantification in proteomics. *bioRxiv* 2023.06.20.545604
- 799 (2023) doi:10.1101/2023.06.20.545604.
- 19. Demichev, V., Messner, C. B., Vernardis, S. I., Lilley, K. S. & Ralser, M. DIA-NN: neural
- 801 networks and interference correction enable deep proteome coverage in high
- throughput. *Nat. Methods* **17**, 41–44 (2019).
- 20. Bruderer, R. et al. Analysis of 1508 Plasma Samples by Capillary-Flow Data-
- 804 Independent Acquisition Profiles Proteomics of Weight Loss and Maintenance. *Mol.*
- 805 *Cell. Proteomics* **18**, 1242–1254 (2019).
- 806 21. Dordevic, N. et al. Pervasive influence of hormonal contraceptives on the human
- 807 plasma proteome in a broad population study. *medRxiv* (2023)
- 808 doi:10.1101/2023.10.11.23296871.
- 22. Tanaka, T. *et al.* Plasma proteomic biomarker signature of age predicts health and life
  span. *Elife* 9, (2020).
- Lehallier, B. *et al.* Undulating changes in human plasma proteome profiles across the
  lifespan. *Nat. Med.* 25, 1843–1850 (2019).
- 813 24. Coenen, L., Lehallier, B., de Vries, H. E. & Middeldorp, J. Markers of aging:
- Unsupervised integrated analyses of the human plasma proteome. *Front Aging* **4**,
- 815 1112109 (2023).
- 816 25. Jenner, J. L. *et al.* Effects of age, sex, and menopausal status on plasma lipoprotein(a)

	spring Study. <i>Circulation</i> <b>87</b> , 1135–1141 (1993	17 levels. The Framingham C
--	--	-----------------------------

- 818 26. Alavi, P. et al. Aging Is Associated With Organ-Specific Alterations in the Level and
- 819 Expression Pattern of von Willebrand Factor. Arterioscler. Thromb. Vasc. Biol. 43,
- 820 2183–2196 (2023).
- 821 27. Huang, Y.-M. *et al.* Plasma β2-microglobulin and cerebrospinal fluid biomarkers of
- 822 Alzheimer's disease pathology in cognitively intact older adults: the CABLE study.
- 823 Alzheimers. Res. Ther. **15**, 69 (2023).
- 28. Swanson, C. R. et al. Plasma apolipoprotein A1 associates with age at onset and motor
- severity in early Parkinson's disease patients. *Mov. Disord.* **30**, 1648–1656 (2015).
- 826 29. Richens, J. L. *et al.* Rationalising the role of Keratin 9 as a biomarker for Alzheimer's
  827 disease. *Sci. Rep.* 6, 22962 (2016).
- 30. Thangaraju, K. et al. The Impact of Age and BMI on the VWF/ADAMTS13 Axis and
- Simultaneous Thrombin and Plasmin Generation in Hospitalized COVID-19 Patients. *Front. Med.* 8, 817305 (2021).
- 831 31. Krawetz, R. J. *et al.* Proteoglycan 4 (PRG4) treatment enhances wound closure and
  832 tissue regeneration. *NPJ Regen Med* 7, 32 (2022).
- 32. Iqbal, S. M. *et al.* Lubricin/Proteoglycan 4 binds to and regulates the activity of Toll-Like
  Receptors In Vitro. *Sci. Rep.* 6, 18910 (2016).
- 33. Alquraini, A. *et al.* The interaction of lubricin/proteoglycan 4 (PRG4) with toll-like
- receptors 2 and 4: an anti-inflammatory role of PRG4 in synovial fluid. *Arthritis Res.*
- 837 *Ther.* **17**, 353 (2015).
- 838 34. Miike, K. *et al.* Proteome profiling reveals gender differences in the composition of
  839 human serum. *Proteomics* **10**, 2678–2691 (2010).
- 840 35. Joaquín, C. et al. Pregnancy-associated plasma protein-A is related to gender and to
- adipocytokine levels: results of the Health Survey of Catalonia. *Clin. Endocrinol.* 78,
  718–723 (2013).
- 36. Gaya da Costa, M. *et al.* Age and Sex-Associated Changes of Complement Activity and
- 844 Complement Levels in a Healthy Caucasian Population. *Front. Immunol.* **9**, 2664 (2018).

- 845 37. Saunders, T. S., Jenkins, N., Blennow, K., Ritchie, C. & Muniz-Terrera, G. Interactions
- between apolipoprotein E, sex, and amyloid-beta on cerebrospinal fluid p-tau levels in
- 847 the European prevention of Alzheimer's dementia longitudinal cohort study (EPAD
- 848 LCS). *EBioMedicine* **83**, 104241 (2022).
- 38. Pek, S. L. T. *et al.* Association of circulating proinflammatory marker, leucine-rich-α2-
- 850 glycoprotein (LRG1), following metabolic/bariatric surgery. *Diabetes. Metab. Res. Rev.*
- **34**, e3029 (2018).
- 39. Riestra, P. et al. Gender-specific associations between ADIPOQ gene polymorphisms
- and adiponectin levels and obesity in the Jackson Heart Study cohort. BMC Med.
- 854 *Genet.* **16**, 65 (2015).
- 40. Pek, S. L. T. *et al.* Elevation of a novel angiogenic factor, leucine-rich-α2-glycoprotein
- 856 (LRG1), is associated with arterial stiffness, endothelial dysfunction, and peripheral
- arterial disease in patients with type 2 diabetes. *J. Clin. Endocrinol. Metab.* **100**, 1586–
  1593 (2015).
- 41. Jaffa, M. A. *et al.* Longitudinal Plasma Kallikrein Levels and Their Association With the
  Risk of Cardiovascular Disease Outcomes in Type 1 Diabetes in DCCT/EDIC. *Diabetes*
- **69**, 2440–2445 (2020).
- 42. Trainor, P. J. et al. Blood Levels of Angiotensinogen and Hypertension in the Multi-
- Ethnic Study of Atherosclerosis (MESA). J. Am. Coll. Cardiol. 81, 1248–1259 (2023).
- 43. Zaghlool, S. B. *et al.* Revealing the role of the human blood plasma proteome in obesity
  using genetic drivers. *Nat. Commun.* 12, 1279 (2021).
- 44. Park, J. et al. Identification of tetranectin as adipogenic serum protein. Biochem.
- 867 Biophys. Res. Commun. **460**, 583–588 (2015).
- 45. Tschoner, A. *et al.* Effect of weight loss on serum pigment epithelium-derived factor
  levels. *Eur. J. Clin. Invest.* 41, 937–942 (2011).
- 46. Gonzalez-Quintela, A. et al. Determinants of serum concentrations of
- 871 lipopolysaccharide-binding protein (LBP) in the adult population: the role of obesity.
- 872 *PLoS One* **8**, e54600 (2013).

- 47. Baez-Duarte, B. G. et al. Serum levels of glutathione peroxidase 3 in overweight and
- obese subjects from central Mexico. Arch. Med. Res. 43, 541–547 (2012).
- 48. Soria-Jasso, L. E. et al. Beneficial and Deleterious Effects of Female Sex Hormones,
- 876 Oral Contraceptives, and Phytoestrogens by Immunomodulation on the Liver. Int. J.
- 877 *Mol. Sci.* **20**, (2019).
- 49. Al-Shanqeeti, A., van Hylckama Vlieg, A., Berntorp, E., Rosendaal, F. R. & Broze, G. J.,
- Jr. Protein Z and protein Z-dependent protease inhibitor. Determinants of levels and risk
  of venous thrombosis. *Thromb. Haemost.* **93**, 411–413 (2005).
- 50. Kangasniemi, M. H. et al. Ethinylestradiol in combined hormonal contraceptive has a
- broader effect on serum proteome compared with estradiol valerate: a randomized
- 883 controlled trial. *Hum. Reprod.* **38**, 89–102 (2023).
- 51. Pattaro, C. *et al.* The Cooperative Health Research in South Tyrol (CHRIS) study:
- rationale, objectives, and preliminary results. *J. Transl. Med.* **13**, 348 (2015).
- 886 52. Boiko, A. S. *et al.* Apolipoprotein serum levels related to metabolic syndrome in patients
  887 with schizophrenia. *Heliyon* 5, e02033 (2019).
- 53. Rahmawati, N. D. et al. Body mass index as a dominant risk factor for metabolic
- syndrome among indonesian adults: a 6-year prospective cohort study of non-
- 890 communicable diseases. *BMC Nutr* **10**, 43 (2024).
- 54. Gray, N., Picone, G., Sloan, F. & Yashkin, A. Relation between BMI and diabetes
  mellitus and its complications among US older adults. *South. Med. J.* 108, 29–36
  (2015).
- 55. Ste Marie, L., Luquet, S., Curtis, W. & Palmiter, R. D. Norepinephrine- and epinephrinedeficient mice gain weight normally on a high-fat diet. *Obes. Res.* 13, 1518–1522
  (2005).
- 56. Sachs, S. *et al.* Plasma proteome profiles treatment efficacy of incretin dual agonism in
  diet-induced obese female and male mice. *Diabetes Obes. Metab.* 23, 195–207 (2021).
- 899 57. Lee, W.-H. *et al.* Genetically predicted plasma cortisol and common chronic diseases: A
- 900 Mendelian randomization study. *Clin. Endocrinol.* **100**, 238–244 (2024).

- 901 58. Moreno-Navarrete, J. M. et al. Lysozyme is a component of the innate immune system
- 902 linked to obesity associated-chronic low-grade inflammation and altered glucose

903 tolerance. *Clin. Nutr.* **40**, 1420–1429 (2021).

- 904 59. Moreno-Navarrete, J. M., Ortega, F. J., Bassols, J., Ricart, W. & Fernández-Real, J. M.
- 905 Decreased circulating lactoferrin in insulin resistance and altered glucose tolerance as a
- 906 possible marker of neutrophil dysfunction in type 2 diabetes. J. Clin. Endocrinol. Metab.
- 907 **94**, 4036–4044 (2009).
- 908 60. Manco, M. et al. The decrease of serum levels of human neutrophil alpha-defensins
- parallels with the surgery-induced amelioration of NASH in obesity. Obes. Surg. 20,
- 910 1682–1689 (2010).
- 911 61. Fernández-Real, J. M. *et al.* CD14 modulates inflammation-driven insulin resistance.
  912 *Diabetes* 60, 2179–2186 (2011).
- 913 62. Spieker, J. et al. Diabetes type 2 in the Berlin Aging Study II: Cross-sectional and

914 longitudinal data on prevalence, incidence and severity over on average seven years of
915 follow-up. *Diabet. Med.* 40, e15104 (2023).

- 916 63. Heidemann, C. & Scheidt-Nave, C. Prevalence, incidence and mortality of diabetes
- 917 mellitus in adults in Germany A review in the framework of the Diabetes Surveillance. *J*
- 918 *Health Monit* **2**, 98–121 (2017).
- 919 64. Ford, E. S., Li, C. & Sattar, N. Metabolic syndrome and incident diabetes: current state
  920 of the evidence. *Diabetes Care* **31**, 1898–1904 (2008).
- 85. Regufe, V. M. G., Pinto, C. M. C. B. & Perez, P. M. V. H. C. Metabolic syndrome in type
  2 diabetic patients: a review of current evidence. *Porto Biomed J* 5, e101 (2020).
- 923 66. Piccirillo, F. et al. Novel Antidiabetic Agents and Their Effects on Lipid Profile: A Single
- 924 Shot for Several Cardiovascular Targets. Int. J. Mol. Sci. 24, (2023).
- 925 67. von Toerne, C. et al. MASP1, THBS1, GPLD1 and ApoA-IV are novel biomarkers
- associated with prediabetes: the KORA F4 study. *Diabetologia* **59**, 1882–1892 (2016).
- 927 68. Begum, M. et al. Adiponectin: A Promising Target for the Treatment of Diabetes and Its
- 928 Complications. *Life* **13**, (2023).

- 929 69. Fisman, E. Z. & Tenenbaum, A. Adiponectin: a manifold therapeutic target for metabolic
- 930 syndrome, diabetes, and coronary disease? *Cardiovasc. Diabetol.* **13**, 103 (2014).
- 931 70. El Khoudary, S. R. Age at menopause onset and risk of cardiovascular disease around
- 932 the world. *Maturitas* **141**, 33–38 (2020).
- 933 71. Schunkert, H. *et al.* Effects of estrogen replacement therapy on the renin-angiotensin
- 934 system in postmenopausal women. *Circulation* **95**, 39–45 (1997).
- 935 72. Umeda, M., Ichikawa, S., Kanda, T., Sumino, H. & Kobayashi, I. Hormone replacement
- 936 therapy increases plasma level of angiotensin II in postmenopausal hypertensive
- 937 women. Am. J. Hypertens. 14, 206–211 (2001).
- 938 73. Victor J. Dzau and Howard C. Herrmann. Hormonal Control of Angiotensinogen
  939 Production. *Life Sciences* (1982).
- 940 74. Katayama, H. et al. Application of serum proteomics to the Women's Health Initiative
- 941 conjugated equine estrogens trial reveals a multitude of effects relevant to clinical
- 942 findings. *Genome Med.* **1**, 47 (2009).
- 943 75. Pitteri, S. J. *et al.* Postmenopausal estrogen and progestin effects on the serum
  944 proteome. *Genome Med.* 1, 121 (2009).
- 945 76. Ho, D. E., Imai, K., King, G. & Stuart, E. A. Matchlt: Nonparametric Preprocessing for
  946 Parametric Causal Inference. *J. Stat. Softw.* 42, (2011).
- 947 77. Guyon, I., Weston, J., Barnhill, S. & Vapnik, V. Gene Selection for Cancer Classification
  948 using Support Vector Machines. *Mach. Learn.* 46, 389–422 (2002).
- 949 78. Ho, T. K. Random decision forests. in *Proceedings of 3rd International Conference on*
- 950 Document Analysis and Recognition (IEEE Comput. Soc. Press, 2002).
- 951 doi:10.1109/icdar.1995.598994.
- 952 79. Niculescu-Mizil, A. & Caruana, R. Predicting good probabilities with supervised learning.
- 953 in Proceedings of the 22nd international conference on Machine learning 625–632
- 954 (Association for Computing Machinery, New York, NY, USA, 2005).
- 80. Eldjarn, G. H. *et al.* Large-scale plasma proteomics comparisons through genetics and
- 956 disease associations. *Nature* **622**, 348–358 (2023).

- 957 81. Sun, B. B. et al. Plasma proteomic associations with genetics and health in the UK
- 958 Biobank. *Nature* **622**, 329–338 (2023).
- 82. Elhadad, M. A. *et al.* Deciphering the Plasma Proteome of Type 2 Diabetes. *Diabetes*69, 2766–2778 (2020).
- 83. Suhre, K., McCarthy, M. I. & Schwenk, J. M. Genetics meets proteomics: perspectives
- 962 for large population-based studies. *Nat. Rev. Genet.* **22**, 19–37 (2021).
- 963 84. Li, X. *et al.* Inflammation and aging: signaling pathways and intervention therapies.
- 964 Signal Transduction and Targeted Therapy **8**, 1–29 (2023).
- 965 85. Di Micco, R., Krizhanovsky, V., Baker, D. & d'Adda di Fagagna, F. Cellular senescence
- 966 in ageing: from mechanisms to therapeutic opportunities. Nat. Rev. Mol. Cell Biol. 22,
- 967 75–95 (2021).
- 86. Moqri, M. *et al.* Biomarkers of aging for the identification and evaluation of longevity
  interventions. *Cell* **186**, 3758–3775 (2023).
- 970 87. Demichev, V. *et al.* A time-resolved proteomic and prognostic map of COVID-19. *Cell*971 Syst **12**, 780–794.e7 (2021).
- 88. Demichev, V. et al. A proteomic survival predictor for COVID-19 patients in intensive
- 973 care. *PLOS Digit Health* **1**, e0000007 (2022).
- 89. Wang, Z. et al. A multiplex protein panel assay for severity prediction and outcome
- 975 prognosis in patients with COVID-19: An observational multi-cohort study.
- 976 *EClinicalMedicine* **49**, 101495 (2022).
- 977 90. Kumar, V. *et al.* Multiplexed quantitative proteomics provides mechanistic cues for
  978 malaria severity and complexity. *Commun Biol* **3**, 683 (2020).
- 979 91. Messner, C. B. *et al.* Ultra-fast proteomics with Scanning SWATH. *Nat. Biotechnol.* 39,
  980 846–854 (2021).
- 981 92. Laxy, M., Teuner, C., Holle, R. & Kurz, C. The association between BMI and health-
- 982 related quality of life in the US population: sex, age and ethnicity matters. *Int. J. Obes.*

**42**, 318–326 (2018).

984 93. GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries

- 985 and territories, 1990-2019: a systematic analysis for the Global Burden of Disease
- 986 Study 2019. Lancet **396**, 1223–1249 (2020).
- 987 94. Cuntz, U., Quadflieg, N. & Voderholzer, U. Health Risk and Underweight. *Nutrients* 15,
  988 (2023).
- 989 95. Stachenfeld, N. S. & Mazure, C. M. Precision medicine requires understanding how
  990 both sex and gender influence health. *Cell* **185**, 1619–1622 (2022).
- 991 96. Kahlert, J., Gribsholt, S. B., Gammelager, H., Dekkers, O. M. & Luta, G. Control of
- confounding in the analysis phase an overview for clinicians. *Clin. Epidemiol.* 9, 195–
  204 (2017).
- 994 97. Sathyan, S. et al. Plasma proteomic profile of frailty. Aging Cell 19, e13193 (2020).
- 98. Weyand, C. M. & Goronzy, J. J. Aging of the Immune System. Mechanisms and
  Therapeutic Targets. *Ann. Am. Thorac. Soc.* **13 Suppl 5**, S422–S428 (2016).
- 997 99. Kassa, F. A. *et al.* New inflammation-related biomarkers during malaria infection. *PLoS*998 One 6, e26495 (2011).
- 999 100.Zinellu, A., Paliogiannis, P., Carru, C. & Mangoni, A. A. Serum amyloid A
- 1000 concentrations, COVID-19 severity and mortality: An updated systematic review and
- 1001 meta-analysis. Int. J. Infect. Dis. **105**, 668–674 (2021).
- 1002 101. Sorić Hosman, I., Kos, I. & Lamot, L. Serum Amyloid A in Inflammatory Rheumatic
- Diseases: A Compendious Review of a Renowned Biomarker. *Front. Immunol.* 11,
  631299 (2020).
- 1005 102.Li, Y. *et al.* Recent Advances in Understanding the Role of Cartilage Lubrication in
  1006 Osteoarthritis. *Molecules* 26, (2021).
- 1007 103.Le Blanc, J. & Lordkipanidzé, M. Platelet Function in Aging. *Front Cardiovasc Med* 6,
  1008 109 (2019).
- 1009 104.La Mendola, D., Trincavelli, M. L. & Martini, C. Angiogenesis in Disease. *Int. J. Mol. Sci.*1010 23, (2022).
- 1011 105.El-Gedaily, A., Schoedon, G., Schneemann, M. & Schaffner, A. Constitutive and
- 1012 regulated expression of platelet basic protein in human monocytes. J. Leukoc. Biol. 75,

- 1013 495–503 (2004).
- 1014 106. Eidet, J. R. et al. The acute phase response protein SERPINA3 is increased in tear fluid
- 1015 from the unaffected eyes of patients with unilateral acute anterior uveitis. *J. Ophthalmic*1016 *Inflamm. Infect.* **11**, 19 (2021).
- 1017 107.Ziegler-Heitbrock, H. W. & Ulevitch, R. J. CD14: cell surface receptor and differentiation
- 1018 marker. *Immunol. Today* **14**, 121–125 (1993).
- 1019 108.Hammond, G. L. Diverse roles for sex hormone-binding globulin in reproduction. *Biol.*1020 *Reprod.* 85, 431–441 (2011).
- 1021 109.Ingenbleek, Y. & Bernstein, L. H. Plasma Transthyretin as a Biomarker of Lean Body
  1022 Mass and Catabolic States. *Adv. Nutr.* 6, 572–580 (2015).
- 1023 110.Walshe, J. M. & Yealland, M. Not Wilson's disease: a review of misdiagnosed cases.
  1024 *QJM* 88, 55–59 (1995).
- 1025 111.Kurachi, S., Deyashiki, Y., Takeshita, J. & Kurachi, K. Genetic mechanisms of age
   regulation of human blood coagulation factor IX. *Science* 285, 739–743 (1999).
- 1027 112.Perdomo, G. & Henry Dong, H. Apolipoprotein D in lipid metabolism and its functional
  1028 implication in atherosclerosis and aging. *Aging* 1, 17–27 (2009).
- 1029 113. Chiellini, C. et al. Serum haptoglobin: a novel marker of adiposity in humans. J. Clin.
- 1030 *Endocrinol. Metab.* **89**, 2678–2683 (2004).
- 1031 114. Kivimäki, M. et al. Body-mass index and risk of obesity-related complex multimorbidity:
- an observational multicohort study. *Lancet Diabetes Endocrinol* **10**, 253–263 (2022).
- 1033 115.Huang, M., Zheng, J., Chen, L., You, S. & Huang, H. Role of apolipoproteins in the 1034 pathogenesis of obesity. *Clin. Chim. Acta* **545**, 117359 (2023).
- 1035 116. Phieler, J. et al. The complement anaphylatoxin C5a receptor contributes to obese
- adipose tissue inflammation and insulin resistance. *J. Immunol.* **191**, 4367–4374 (2013).
- 1037 117.Farztdinov, V. et al. Role of the complement system in Long COVID.
- 1038 doi:10.1101/2024.03.14.24304224.
- 1039 118.Yu, Y. et al. Bioinformatics analysis of candidate genes and potential therapeutic drugs
- 1040 targeting adipose tissue in obesity. *Adipocyte* **11**, 1–10 (2022).

1041 119.Schaefer, B. A., Cheng, D. & Kouides, P. Impact of obesity on factor VIII and von
Willebrand factor levels in patients with Type 1 von Willebrand disease and low von
Willebrand factor: An analysis of the ATHNdataset. *Haemophilia* 28, 109–116 (2022).
1044 120.Xu, K. *et al.* Elevated extracellular matrix protein 1 in circulating extracellular vesicles
supports breast cancer progression under obesity conditions. *Nat. Commun.* 15, 1685
1046 (2024).

- 1047 121.Zanato, V. *et al.* Weight loss reduces anti-ADAMTS13 autoantibodies and improves
  1048 inflammatory and coagulative parameters in obese patients. *Endocrine* 56, 521–527
  1049 (2017).
- 1050 122. Moebus, S. *et al.* Assessing the prevalence of the Metabolic Syndrome according to

NCEP ATP III in Germany: feasibility and quality aspects of a two step approach in 1550
 randomly selected primary health care practices. *Ger. Med. Sci.* 4, Doc07 (2006).

1053 123.Moebus, S. *et al.* Regional differences in the prevalence of the metabolic syndrome in 1054 primary care practices in Germany. *Dtsch. Arztebl. Int.* **105**, 207–213 (2008).

1055 124. Cheng, C.-W., Chang, C.-C., Chen, H.-W., Lin, C.-Y. & Chen, J.-S. Serum ApoA4 levels

- predicted the progression of renal impairment in T2DM. *Eur. J. Clin. Invest.* 48, e12937
  (2018).
- 1058 125. Desmarais, F. *et al.* High ApoD protein level in the round ligament fat depot of severely
  1059 obese women is associated with an improved inflammatory profile. *Endocrine* 61, 248–
  1060 257 (2018).
- 1061 126.Curry, M. D., McConathy, W. J. & Alaupovic, P. Quantitative determination of human
  1062 apolipoprotein D by electroimmunoassay and radial immunodiffusion. *Biochim. Biophys.*1063 *Acta* 491, 232–241 (1977).
- 1064 127.Lim, Y. et al. Apolipoprotein B Is Related to Metabolic Syndrome Independently of Low
- Density Lipoprotein Cholesterol in Patients with Type 2 Diabetes. *Endocrinol Metab*(Seoul) 30, 208–215 (2015).
- 1067 128. Waldner, A., Dassati, S., Redl, B., Smania, N. & Gandolfi, M. Apolipoprotein D
- 1068 Concentration in Human Plasma during Aging and in Parkinson's Disease: A Cross-

1069 Sectional Study. *Parkinsons Dis.* **2018**, 3751516 (2018).

- 1070 129. Pirim, D. et al. Apolipoprotein E-C1-C4-C2 gene cluster region and inter-individual
- 1071 variation in plasma lipoprotein levels: a comprehensive genetic association study in two
- 1072 ethnic groups. *PLoS One* **14**, e0214060 (2019).
- 1073 130.Kim, S. Y., Park, S. M. & Lee, S.-T. Apolipoprotein C-II is a novel substrate for matrix
- 1074 metalloproteinases. *Biochem. Biophys. Res. Commun.* **339**, 47–54 (2006).
- 1075 131.Li, J. *et al.* Association of apolipoprotein Cs with new-onset type 2 diabetes mellitus:
- 1076 findings from the Chinese multi-provincial cohort study. *BMJ Open* **11**, e052388 (2021).
- 1077 132. Ryoo, J.-H. & Park, S. K. Association of apolipoprotein B and incidence of metabolic
- 1078 syndrome in Korean men: a 5-years' follow-up study. *Atherosclerosis* 226, 496–501
  1079 (2013).
- 1080 133.Basavaraju, P. *et al.* Genetic Regulatory Networks of Apolipoproteins and Associated
  1081 Medical Risks. *Front Cardiovasc Med* 8, 788852 (2021).
- 1082 134.Haas, M. E., Attie, A. D. & Biddinger, S. B. The regulation of ApoB metabolism by
  1083 insulin. *Trends Endocrinol. Metab.* 24, 391–397 (2013).
- 1084 135.Babu, A. & Fogelfeld, L. Metabolic syndrome and prediabetes. *Dis. Mon.* 52, 55–144
  1085 (2006).
- 136.Nesic, J. *et al.* Adiponectin and Interleukin-33: Possible Early Markers of Metabolic
  Syndrome. *J. Clin. Med. Res.* **12**, (2022).
- 1088 137. Snijder, M. B. et al. Associations of adiponectin levels with incident impaired glucose
- metabolism and type 2 diabetes in older men and women: the hoorn study. *Diabetes Care* 29, 2498–2503 (2006).
- 1091 138.Roark, E. F. et al. The association of human fibulin-1 with elastic fibers: an
- 1092 immunohistological, ultrastructural, and RNA study. *J. Histochem. Cytochem.* 43, 401–
  1093 411 (1995).
- 1094 139. Jie, Y. et al. The clinical value of Fibulin-1 for prognosis and its prospective mechanism

1095 in intrahepatic cholangiocarcinoma. *HPB* **21**, 499–507 (2019).

1096 140.Liangpunsakul, S. et al. Novel serum biomarkers for detection of excessive alcohol use.

1097 Alcohol. Clin. Exp. Res. **39**, 556–565 (2015).

- 141.Ohlmeier, S. *et al.* Sputum proteomics identifies elevated PIGR levels in smokers and
   mild-to-moderate COPD. *J. Proteome Res.* **11**, 599–608 (2012).
- 1100 142.McGrath, J. J. C. et al. Cigarette smoke exposure attenuates the induction of antigen-
- specific IgA in the murine upper respiratory tract. *Mucosal Immunol.* **14**, 1067–1076
- 1102 (2021).
- 1103 143. Poussin, C. et al. Blood and urine multi-omics analysis of the impact of e-vaping,
- smoking, and cessation: from exposome to molecular responses. *Sci. Rep.* 14, 4286
  (2024).
- 1106 144. Tangada, S. D. et al. The effect of smoking on serum IgG2 reactive with Actinobacillus
- actinomycetemcomitans in early-onset periodontitis patients. *J. Periodontol.* 68, 842–
  850 (1997).
- 1109 145. Tilly, P. et al. Biological and genetic determinants of serum apoC-III concentration:

reference limits from the Stanislas Cohort. J. Lipid Res. 44, 430–436 (2003).

- 1111 146. Wilkens, T. L. et al. Associations between Alcohol Consumption and HDL Subspecies
- 1112 Defined by ApoC3, ApoE and ApoJ: the Cardiovascular Health Study. *Curr. Probl.*
- 1113 *Cardiol.* **48**, 101395 (2023).
- 1114 147.Grimaldi, F., De Marchi, S. & Cecchin, E. [Low T4 syndrome in alcoholism: role of the
  1115 decrease in TBG]. *Minerva Med.* 77, 381–385 (1986).
- 148.Song, Y. *et al.* Associations of the APOC3 rs5128 polymorphism with plasma APOC3
  and lipid levels: a meta-analysis. *Lipids Health Dis.* 14, 32 (2015).
- 1118 149.Lecomte, E. et al. Changes in serum apolipoprotein and lipoprotein profile induced by
- 1119 chronic alcohol consumption and withdrawal: determinant effect on heart disease? *Clin.*
- 1120 *Chem.* **42**, 1666–1675 (1996).
- 1121 150. Shaish, A. et al. Alcohol increases plasma levels of cholesterol diet-induced atherogenic
- 1122 lipoproteins and aortic atherosclerosis in rabbits. *Arterioscler. Thromb. Vasc. Biol.* 17,
- 1123 1091–1097 (1997).
- 1124 151. Geurts, J. et al. Alterations in circulating thyroid hormones and thyroxine binding

- 1125 globulin in chronic alcoholism. *Clin. Endocrinol.* **14**, 113–118 (1981).
- 1126 152. Marino, L., Kim, A., Ni, B. & Celi, F. S. Thyroid hormone action and liver disease, a
- 1127 complex interplay. *Hepatology* (2023) doi:10.1097/HEP.00000000000551.
- 1128 153. Glinoer, D., Gershengorn, M. C. & Robbins, J. Thyroxine-binding globulin biosynthesis
- in isolated monkey hepatocytes. *Biochim. Biophys. Acta* **418**, 232–244 (1976).
- 1130 154. Josse, A. R., Garcia-Bailo, B., Fischer, K. & El-Sohemy, A. Novel effects of hormonal
- 1131 contraceptive use on the plasma proteome. *PLoS One* **7**, e45162 (2012).
- 1132 155.Briggs, M. H. & Briggs, M. Oral Contraceptives and plasma protein metabolism. *Journal*
- 1133 of Steroid Biochemistry **11**, 525–428 (1979).
- 1134 156. Clemente, C. et al. Ceruloplasmin serum level in post-menopausal women treated with
- 1135 oral estrogens administered at different times. *Horm. Metab. Res.* 24, 191–193 (1992).
- 1136 157. Melissari, E. & Kakkar, V. V. The effects of oestrogen administration on the plasma free

1137 protein S and C4b-binding protein. *Thromb. Res.* **49**, 489–495 (1988).

- 1138 158.Godsland, I. F. Effects of postmenopausal hormone replacement therapy on lipid,
- 1139 lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from
- 1140 1974-2000. *Fertil. Steril.* **75**, 898–915 (2001).
- 1141 159. Bayrak, A., Aldemir, D. A., Bayrak, T., Corakçi, A. & Dursun, P. The effect of hormone
- 1142 replacement therapy on the levels of serum lipids, apolipoprotein AI, apolipoprotein B
- and lipoprotein (a) in Turkish postmenopausal women. Arch. Gynecol. Obstet. 274,
- 1144 289–296 (2006).
- 1145 160. Yang, H. K. *et al.* Different effect of alcohol consumption on hypertension according to
  1146 metabolic health status. *J. Hum. Hypertens.* **30**, 591–598 (2016).
- 1147 161.Wakabayashi, I. Associations of alcohol drinking and cigarette smoking with serum lipid
  1148 levels in healthy middle-aged men. *Alcohol Alcohol 43*, 274–280 (2008).
- 1149 162.Burger, M., Brönstrup, A. & Pietrzik, K. Derivation of tolerable upper alcohol intake
- 1150 levels in Germany: a systematic review of risks and benefits of moderate alcohol
- 1151 consumption. *Prev. Med.* **39**, 111–127 (2004).
- 1152 163.German Federal Ministry of Health. Alcohol and alcohol dependence.

1153 https://gesund.bund.de/en/alcohol.

- 1154 164.Nöthlings, U., Hoffmann, K., Bergmann, M. M. & Boeing, H. Fitting portion sizes in a
- self-administered food frequency questionnaire. J. Nutr. **137**, 2781–2786 (2007).
- 1156 165. American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards

1157 of Medical Care in Diabetes-2019. *Diabetes Care* **42**, S13–S28 (2019).

- 1158 166. Alberti, K. G. M. M. *et al.* Harmonizing the metabolic syndrome: a joint interim statement
- 1159 of the International Diabetes Federation Task Force on Epidemiology and Prevention;
- 1160 National Heart, Lung, and Blood Institute; American Heart Association; World Heart
- 1161 Federation; International Atherosclerosis Society; and International Association for the

1162 Study of Obesity. *Circulation* **120**, 1640–1645 (2009).

- 1163 167.Meier, F. *et al.* diaPASEF: parallel accumulation-serial fragmentation combined with
- 1164 data-independent acquisition. *Nat. Methods* **17**, 1229–1236 (2020).
- 1165 168.UniProt Consortium. The universal protein resource (UniProt). *Nucleic Acids Res.* 36,
  1166 D190–5 (2008).
- 1167 169.Koopmans, F., Li, K. W., Klaassen, R. V. & Smit, A. B. MS-DAP Platform for
- 1168 Downstream Data Analysis of Label-Free Proteomics Uncovers Optimal Workflows in
- 1169 Benchmark Data Sets and Increased Sensitivity in Analysis of Alzheimer's Biomarker
- 1170 Data. J. Proteome Res. 22, 374–386 (2023).
- 1171 170.Ballman, K. V., Grill, D. E., Oberg, A. L. & Therneau, T. M. Faster cyclic loess:
- 1172 normalizing RNA arrays via linear models. *Bioinformatics* **20**, 2778–2786 (2004).
- 1173 171. Stacklies, W., Redestig, H., Scholz, M., Walther, D. & Selbig, J. pcaMethods -- a
- 1174 Bioconductor package providing PCA methods for incomplete data. *Bioinformatics* vol.
- 1175 23 1164–1167 Preprint at (2007).
- 1176 172. Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing
- 1177 and microarray studies. *Nucleic Acids Res.* **43**, e47 (2015).
- 1178 173. Troyanskaya, O. et al. Missing value estimation methods for DNA microarrays.
- 1179 *Bioinformatics* **17**, 520–525 (2001).
- 1180 174.Bolstad, B. preprocessCore: a collection of pre-processing functions. R package version

1181 1.46. 0. Preprint at (2019).

- 1182 175.Mi, H., Muruganujan, A., Casagrande, J. T. & Thomas, P. D. Large-scale gene function
- analysis with the PANTHER classification system. *Nat. Protoc.* **8**, 1551–1566 (2013).
- 1184 176.Pedregosa, F. et al. Scikit-learn: Machine Learning in Python. J. Mach. Learn. Res. 12,
- 1185 2825–2830 (2011).
- 1186 177. Seabold, S. & Perktold, J. Statsmodels: Econometric and statistical modeling with
- 1187 python. in *Proceedings of the 9th Python in Science Conference* (SciPy, 2010).
- 1188 doi:10.25080/majora-92bf1922-011.
- 1189 178. Virtanen, P. *et al.* SciPy 1.0: fundamental algorithms for scientific computing in Python.
- 1190 *Nat. Methods* **17**, 261–272 (2020).
- 1191 179.Perez-Riverol, Y. *et al.* The PRIDE database and related tools and resources in 2019:
- improving support for quantification data. *Nucleic Acids Res.* **47**, D442–D450 (2019).

#### 1193 Supplementary Material

PDF document contains Supplementary Figures S1-S260 and Supplementary Tables S1 and S6-S12. Spreadsheets (xlsx) with Supplementary Table S2 contains functional annotations of protein groups present in the dataset. Tables S3-S5 contain results of association analysis for the whole cohort and the younger and older age group, respectively.

#### 1198 Data Availability Statement

BASE-II proteome data is available only upon reasonable request. Please contact LudmilaMüller, scientific coordinator, at Imueller@mpib-berlin.mpg.de, for additional information.

1201 The raw mass spectrometry data of study pools and standardized, commercially available 1202 serum set sample as well as the raw DIA-NN output and used FASTA file for spectral library 1203 annotation will be deposited to the ProteomeXchange Consortium via the PRIDE partner 1204 repository<sup>179</sup> upon publication.

#### 1205 Acknowledgements

The authors of this paper thank all study participants of the Berlin Aging Study II, as well as all people involved in planning this study, executing sample collection, conducting questionnaire survey and preparing the data. We thank the Charité Core Facility High Throughput Mass Spectrometry for conducting the measurements. We thank Vivien Bahr for clinical background information regarding glucose lowering drugs and Oliver Lemke for inspiration on how to visualize a 2-feature random forest.

1212 Funding

1213 BASE-II was supported by the German Federal Ministry of Education and Research under 1214 grant numbers #01UW0808: #16SV5536K, #16SV5537, #16SV5538, #16SV5837, 1215 #01GL1716A, and #01GL1716B. This work was supported by a grant of the Deutsche 1216 Forschungsgemeinschaft (grant number 460683900 to ID). The proteomic work presented here was supported by the Ministry of Education and Research (BMBF), as part of the National 1217 1218 Research Node 'Mass spectrometry in Systems Medicine (MSCoresys), under grant 1219 agreement 031L0220 and 16LW023K, as well as the the German Cancer Consortium (DKTK) 1220 under agreement BE01 1020000483.

- 1221 1222
- 1223 Competing Interest Statement

1224 Markus Ralser is founder and shareholder of Eliptica Ltd. Michael Mülleder is a consultant and 1225 shareholder of Eliptica Ltd.

1226 Ethics: Institutional Review Board Statement

All participants gave written informed consent. The Ethics Committee of the Charité – Universitätsmedizin Berlin approved the study (approval number EA2/029/09). The study was conducted in accordance with the Declaration of Helsinki and was registered in the German Clinical Trials Registry as DRKS00009277.

1231 Author Contributions

Conceptualization: M.R., I.D., C.D., R.S.M.; Investigation: K.T., D.L., O.S., V.F., M.M.; Formal
Analysis: C.D., R.S.M., O.S., V.F., M.M., J.R.; Writing – original draft preparation: C.D.,
R.S.M., O.S., K.T.; Writing – review and editing: C.D., R.S.M., O.S., J.R., I.D., M.R.; Funding
acquisition: I.D., M.R.